ThromboGenics Struggles to Find Patients for Phase II Eye Disease Trial Post author:Sam Post published:December 7, 2017 Post category:BioPharma Resources redirected to progress new drug candidates to clinic in H1 2018. Source: BioSpace You Might Also Like Zymeworks Appoints Dr. To Its Board Of Directors August 2, 2017 Celgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials December 28, 2017 These 2 Biotechs' Shark Antibodies Have Caught Amgen's Eye May 8, 2017
